Autolus Therapeutics Posts $75M First-Year Launch, Sees $120M–$135M in 2026
Autolus Therapeutics generated $75 million in first-year revenue for obe-cel and achieved market leadership by Q2 across about 70 U.S. centers. The company forecasts $120 million to $135 million net revenue in 2026 with positive gross margin in year two driven by manufacturing efficiencies.
1. First-Year Commercial Launch
Autolus Therapeutics entered its second commercial year with obe-cel, generating $75 million in first-year revenue and securing market leadership by Q2. The therapy is available in approximately 70 U.S. centers, with plans to expand to over 80 centers throughout the year.
2. 2026 Revenue Guidance and Margin Outlook
For 2026, the company targets $120 million to $135 million in net revenue and expects to achieve positive gross margin in year two. Margin improvement is driven by manufacturing scale, reduced hours per product and supply chain optimizations.
3. Regulatory Approvals and Market Access
The company obtained approvals in the U.K. with positive NICE coverage and launched obe-cel in routine commissioning, while European market access negotiations are ongoing. No revenue guidance for Europe has been provided pending reimbursement agreements.
4. Manufacturing Performance and Optimization
Manufacturing success exceeded 90% in year one at the U.K. facility, with no current capacity constraints. Autolus is implementing advanced automation and process improvements to reduce production time and costs over the next 24–36 months.